A New Medicine for Lung Injury Caused by Sulfur Mustard Exposure
Official title: A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury
Funded at Cmtx Biotech, INC. · NIH-11135448 · Data updated 2026-11-12
This project is developing a new oral medicine, incyclinide, to help people recover from lung injuries caused by exposure to sulfur mustard.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project start | July 9, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $295,715 |
| NIH project number | 5R41AI187083-02 |
| Project ID | NIH-11135448 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for future clinical applications would be individuals who have experienced lung injury due to exposure to sulfur mustard or similar vesicant agents.
✕Less likely to help
Patients with lung injuries from causes other than sulfur mustard exposure may not receive benefit from this specific treatment.
What this research studies
This research focuses on creating a new oral medication called incyclinide, which is a specially modified tetracycline, to treat lung damage from sulfur mustard exposure. Sulfur mustard is a chemical agent that can cause severe blistering and injury to the lungs, skin, and eyes. The goal is to develop a 'host-directed' treatment, meaning it works by helping your body's own defenses respond to the injury, rather than directly fighting an infection. This medicine aims to reduce the severe inflammation and tissue damage that occurs in the lungs after exposure. If successful, it could offer a vital medical countermeasure for those affected by chemical warfare or industrial accidents.
Why it matters
Potential benefit: If successful, this new medicine could significantly reduce lung damage and improve recovery for individuals exposed to sulfur mustard.
How similar studies have gone: Chemically modified tetracyclines have shown promise in other inflammatory conditions, and incyclinide is already in clinical stages for other uses, suggesting a foundation for this approach.
Where this research is happening
-
Cmtx Biotech, INC.
Kings Park, United States Active
Researchers
- Principal investigator: Veress, Livia Agnes — Cmtx Biotech, INC.
- Study coordinator: Veress, Livia Agnes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.